| 摘要 |
Agents which influence the partitioning of dietary lipids between the liver and peripheral tissues for use as medicaments. 7 polypeptide sequences ( the sequences relate to complement C1qA, complement C1qB, complement C1qC, multimerin, cerebellin, ApM1, AdipoQ and acrp30) and two consensus sequences are given in the specification and are potentially useful as these agents. An agent is claimed which influences the partitioning of dietary lipids between the liver and peripheral tissues for use as a medicament. Independent claims are included for: (1) a polypeptide comprising a consensus sequence selected from sequence (I): PheX(5) AsnAspX(4) PheTyrTrpLeuX(6) PheX(5)GlyXTyrXPhe XPheTyr and (II): SerThrXPheSerThr GlyPheTyrLeuLeuVal PheTyr for use as a medicament; (2) a polypeptide comprising an amino acid sequence selected from polypeptides having at least 25%, 50% or 80% homology to one of the sequences (VII)-(XIV) given in the specification, for use as a medicament; (3) a C1q polypeptide, derivative, homologue or a fragment of any of the preceding compounds for use as a medicament; (4) an AdipoQ polypeptide or a derivative, homologue or fragment for use as a medicament; (5) an ApM1 polypeptide, derivative, homologue or fragment for use as a medicament; (6) a composition for modulating the activity of LSR comprising a compound having binding specificity for the gC1q.R protein, where the compound is not a subunit of the LSR; and a carrier; (7) a method of reducing plasma lipoprotein levels in an animal comprising: (a) identifying an animal having a measurable plasma lipoprotein level; (b) administering to the animal a composition that includes a carrier and a polypeptide that is at least 25% homologous to an ApM1 protein; and (c) allowing passage of a period of time to permit reduction in the measurable plasma lipoprotein level; (8) a method for treating an animal having a condition in which it is desirable to increase the partitioning of dietary lipids to the liver, comprising administering an LSR agonist to the animal having the condition; (9) a method for treating an animal having a condition in which it is desirable to decrease the partitioning of dietary lipids to the liver, comprising administering an LSR antagonist to the animal having the condition; (10) an agent which increases the activity of a compound which increases the partitioning of dietary lipids to the liver for use as a pharmaceutical; (11) an agent which decreases the activity of a compound which increases the partitioning of dietary lipids to the liver for use as a pharmaceutical; (12) a method for decreasing the partitioning of dietary lipids to the liver comprising administering an agent which decreases the activity of a compound selected from adipoQ, ApM1, C1q, compounds comprising at least one sequence selected from sequences (I) and (II), compounds comprising an amino acid sequence having at least 25% homology to a sequence selected from sequences (VII)-(XIV) given in the specification, (129, 130, 124, 130, 130, 130, 130, and 126 amino acids respectively), polypeptides comprising an amino acid sequence having at least 50% homology to a sequence selected from sequences (VII)-(XIV), and polypeptides comprising an amino acid sequence having at least 80% homology to a sequence selected from sequences (VII)-(XIV).
|
